Identification and assessment of breathlessness in clinical practice: a systematic review and narrative synthesis.

Helene L. Elliott-Button BSc (Hons) MSc¹, Miriam J. Johnson MD FRCP MBChB (Hons)¹, Ugochinyere Nwulu BSc MPH¹, Joseph Clark BA MA PhD¹

Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, United Kingdom.

Corresponding author: Helene Elliott-Button (hyhb7@hyms.ac.uk)
Wolfson Palliative Care Research Centre, Hull York Medical School, Allam Medical Building, University of Hull, Hull, HU6 7RX

Number of tables: 2
Number of figures: 2
Number of references: 74
Word count: 3687 (excluding abstract, figures, tables, references, and title page)
ABSTRACT

Context
Breathlessness is common in chronic conditions but often goes unidentified by clinicians. It is important to understand how identification and assessment of breathlessness occurs across healthcare settings, to promote routine outcome assessment and access to treatment.

Objective
To summarise how breathlessness is identified and assessed in adults with chronic conditions across different healthcare settings.

Methods
This is a systematic review and descriptive narrative synthesis (PROSPERO registration: CRD42018089782). Searches were conducted on Medline, PsycINFO, Cochrane Library, Embase and CINAHL (2000-2018) and reference lists. Screening was conducted by two independent reviewers, with access to a third, against inclusion criteria. Data were extracted using a bespoke proforma.

Results
Ninety-seven studies were included; conducted in primary care (n=9), secondary care (n=53) and specialist palliative care (n=35). Twenty-five measures of identification and 41 measures of assessment of breathlessness were used. Primary and secondary care used a range of measures to assess breathlessness severity, cause, and impact for people with chronic obstructive pulmonary disease (COPD). Specialist palliative care used measures assessing broader symptom severity and function with less focus on overall quality of life (QoL). Few studies were identified from primary care.

Conclusion
Various measures were identified, reflective of the setting’s purpose. However, this highlights missed opportunities for breathlessness management across settings; primary care is particularly well-placed to diagnose and support breathlessness. The COPD approach (where
symptoms and QoL are part of disease management) could apply to other conditions. Better documentation of holistic patient-reported measures may drive service improvement in specialist palliative care.

249/250 words

Key words: dyspnea, breathlessness, chronic breathlessness syndrome, identification, assessment, patient reported outcome measures
INTRODUCTION

Breathlessness is defined by the American Thoracic Society as “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity” (1). Breathlessness is common in the general population (2) and in people with cardiorespiratory conditions and cancer; (3, 4) relevant in all healthcare settings. Breathlessness has a widespread impact on the patient and their family. (5-7) It is associated with poor quality of life, (8) poor survival (9) and increased emergency care and hospital admissions (10-12) with increased hospital length of stay and in-hospital adverse events. (13, 14) Recognition that breathlessness may be persistent and disabling despite optimal treatment of the causative medical condition, has led to recent naming and defining of chronic breathlessness syndrome. (15)

Evidence-based interventions and clinical frameworks to aid assessment of breathlessness (16) and assessment and management of chronic breathlessness are available. (17) Access to, and use of, these may improve patient and family experience, support clinicians to be more effective, and lessen pressure on the health system and resources. The identification and assessment of breathlessness in all clinical settings is therefore important, but not conducted systematically in clinical practice (18) and tends not to be reported by patients routinely. (19) As patients usually appear comfortable at rest, practitioners may not identify this symptom (20) without specific enquiry. (21) Therefore, breathlessness is all too often ‘invisible’, (19, 21) and unmanaged in clinical practice in spite of its negative impact.

A number of tools or tests can be used in clinical practice to identify the presence or measure breathlessness severity and the impact on the individual’s physical and mental quality of life or functional status, as well as the cause of the breathlessness (22-24). However, little is known about how these are used in clinical practice across healthcare settings and how they vary according to the main purpose of care; 1) primary care for initial presentation, referral and ongoing management of disease and symptom management of chronic breathlessness; 2) secondary care for diagnosis and ongoing management of disease and symptom management of chronic breathlessness; and 3) palliative care for symptom management of chronic breathlessness, maintenance of function and support for other symptoms or concerns in advanced disease.
Routine outcome measurement of problems like breathlessness can help to drive service improvement. (25) Clinical audits and research can help to demonstrate service effectiveness or identify areas for improvement. As management of long-term conditions is an increasing necessity across nations, outcome measurement can help provide evidence to clinical commissioners of the need for resources. (25)

We therefore reviewed the published literature presenting data on the identification and assessment of breathlessness in clinical practice, across health care settings.

METHODS

This systematic literature review and descriptive narrative synthesis was reported in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (26). The protocol is registered on PROSPERO (CRD42018089782).

Information Sources and Search Strategy

A search strategy was formulated using MeSH headings and keywords in relation to breathlessness and patient reported outcomes (Supplementary File 1). A sensitive (retrieving higher results), rather than specific (more precise, less results) approach was taken, to retrieve as many results as possible.

Five databases, MEDLINE (Ovid), PsycINFO (Ovid), Cochrane Library, Embase (Ovid) and CINAHL (EBSCO), were searched between 2000 and 19 February 2018 and reference lists of relevant articles hand searched. A date filter of 2000 was set to ensure results were relevant to current clinical practice.

Inclusion and Exclusion Criteria

Inclusion and exclusion criteria were established to identify the range of measures used to identify and assess breathlessness across healthcare settings, as reflected by primary research studies conducted in routine clinical practice (Table 1).
Study Selection

Titles and abstracts were reviewed against the inclusion criteria by two independent researchers (HE, UN) with recourse to JC and MJ in the case of disagreement. Where decisions could not be made from the titles and abstracts, full texts were retrieved, and the same process followed. Full texts were then sourced and reviewed by the same two independent reviewers, with arbitration to JC and MJ if disagreement occurred. Independent second reviewing included 10% of title/abstract and full texts with high levels of agreement.

As effectiveness outcomes of studies were not being considered, no formal quality assessment was conducted. However, it was noted whether or not any measures found had been psychometrically validated.

Data Extraction

Data were extracted using a piloted form to collect: author, title, year, setting, geographic location, study design, sample size, age, health conditions, and measures of identifying and assessing breathlessness. Many studies did not report population age range, but only the mean and standard deviation which were all >18 years. We have therefore made an assumption that the population was adult. Individual study outcomes were not collected, as this did not address our research question. The first 10% of data extraction (consecutive papers) were checked for accuracy and consistency by UN. There were no disagreements and so no further double data extraction was conducted.

Study Settings

Included studies were grouped by health care setting, reflective of their purpose:

i) Primary care; this included general practice and long-term care facilities assuming most received their medical care from community services. This setting is commonly associated with initial presentation, referral, and ongoing care.

ii) Secondary care; this included all studies set in hospital-based services, whether secondary or tertiary care, such as outpatients, inpatients, emergency departments and rehabilitation services. This is associated with diagnosis and ongoing management.
iii) Specialist palliative care (SPC); this included specialist palliative care services whether provided in community, hospital, or hospice settings. Commonly associated with symptom management, maintenance of function and holistic support in advanced disease.

Categorisation of Measures Identifying and Assessing Breathlessness

Measures were categorised and described as those able to identify: the presence or absence of breathlessness; those that assessed the symptom severity; those that assessed the impact of the symptom; and tests to help assess the underlying cause of the symptom. Some were able to both identify presence/absence and measure aspects of the symptom. For example, the Visual Analogue Scale tests both presence/absence and the amount of breathlessness, and the modified Medical Research Council [mMRC] scale could identify presence/absence and gave a measure of the impact on physical exertion. Where a measure/test could be counted in more than one category, they were counted in both.

Description was used to present the included studies and narrative synthesis was used to analyse the findings. Included studies were grouped by study setting, noting the primary diagnosis of study participants. Measures of identification and assessment of breathlessness were grouped by their purpose (symptom severity, impact of symptom, cause of symptom) and by study setting. It was not possible to distinguish between measures identifying breathlessness and chronic breathlessness specifically. Therefore, throughout the manuscript, we refer to breathlessness. However, in circumstances where breathlessness is likely to be chronic, for example in COPD pulmonary rehabilitation or palliative care, where treatment of underlying cause is likely to have been optimised, we infer chronic breathlessness as appropriate.

RESULTS

Included Studies

The search strategy returned 19,062 articles. Three additional articles were identified through reference searching (n=19,065). Duplicates (n=6,561) were removed and two independent authors (HE and UN) screened the remaining 12,504 articles by title and abstract, of which 12,356 were excluded. Following full text review and discussion, 97 articles
were included (See Figure 1 for PRISMA flowchart and Appendix C for reference list of included studies).

**General Characteristics of Studies**

Studies were conducted from 2000 – 2018, the numbers per year increasing with time. Studies were conducted in North America (n=49 [50.5%]); Europe (n=38 [39.2%]; 15 from the UK [15.5%]), Asia (n = 9 [9.3%]) and one from Australia [1%]. All studies were observational and included case note assessment/chart reviews/medical records review (n=36 [37%]), retrospective cohort/studies (n=30 [31%]), longitudinal/prospective cohort studies (n=11 [11.3%]), audits/clinical audits (n=6 [6.2%]), evaluations/service evaluations (n=5 [5.2%]), cross-sectional studies (n=3 [3.1%]), database review (n=3 [3.1%]), descriptive analysis (n=2 [2.1%]) and case-series study (n=1 [1%]) (Supplementary File 2). Studies varied widely in their sample size, ranging from seven to 67,362 participants.

**Health Care Setting**

Most studies reporting approaches to the identification and assessment of breathlessness were in the secondary care (n=53 [54.6%]) setting, followed by SPC (n=35 [36.1%]). Very few studies were in the primary care setting (n=9 [9.3%]) [Figure 2].

**Primary Health Conditions**

Most included studies reported the identification and assessment in the context of a diagnosis of COPD (Chronic obstructive pulmonary disease; n=31 [32%]) or cancer (n=30 [31%]). Of the others, the most common were studies reporting a range of primary medical conditions (n = 17 [17.5%]), interstitial lung diseases (n = 7 [7.2%]) or heart failure (n = 4 [4.1%]).

**Measures of Identification of Presence or Absence of Breathlessness**

Of the 97 studies, 93 (95.9%) reported at least one breathlessness measure or other method of enquiry of identifying breathlessness in clinical use. There were 25 distinct measures of identifying breathlessness reported by included studies (Appendix B). The top three most frequently used measures were the MRC or mMRC (Medical Research Council
Dyspnoea Scale, or modified version) [used in 27 studies (27.8%)], ESAS (Edmonton Symptom Assessment Scale, or variant) [n=22 (22.7%)], and BORG (or variant) [n=13 (13.4%)]. Only two measures were used across all three health care settings; CAT (COPD Assessment Test) [primary care n=2 (2.1%), secondary care n=4 (4.1%), SPC n=1 (1%)], and where breathlessness was identified but the method was not described [primary care n=1 (1%), secondary care n=7 (7.2%), SPC n=3 (3.1%)].

In addition, some studies only used clinician assessment (history/examination/observation) (n=9; 9.3%), patient volunteered symptom (n=4; 4.1%) or where breathlessness was identified but the method was not described (n=11; 11.3%).

Measures of Assessment of Breathlessness (symptom severity, impact of symptom, cause of symptom)

Of the 97 studies, 85 (87.6%) reported at least one measure of assessing breathlessness (symptom severity, impact, or cause). There were 41 distinct measures in clinical use across settings (Appendix B). The most common measures reported overall were LFM (Lung Function Measurements) [used in 41 studies (42.3%)], MRC [n=27 (27.8%)] and ESAS [n=22 (22.7%)]. Only two measures were used across all health care settings; LFM [primary care n=8 (8.2%), secondary care n=30 (30.9%), SPC n=3 (3.1%)] and CAT [primary care n=2 (2.1%), secondary care n=4 (4.1%), SPC n=1 (1%)].

Measures of the symptom severity were most common (studies n=70; 72.2%); followed by measures of the impact of breathlessness such as quality of life, patient concerns or functional status (n=55; 56.7%); and lastly, measures of the underlying cause/diagnosis of breathlessness (n=47; 48.5%). A summary of symptom severity, impact, and cause measures of assessment by health care settings can be found in Table 2 (see Appendices A and B for detailed lists).

Validation of Measures

Of the measures used for both identification and assessment of breathlessness, the majority were validated tools (n=26), some were adaptations or simplified versions of scales, and many were medical tests (n=13).
DISCUSSION

Most published literature since 2000 regarding the identification and measurement of breathlessness in clinical practice is from the secondary care and palliative care setting. Fewer than one in ten studies were from primary care. Nearly all studies used some form of identification of presence or absence of the symptom. However, the pattern of symptom severity assessment, impact of symptom and diagnostic tests varied by clinical setting, in part reflecting the setting’s purpose. Thus, primary care and secondary care studies reported a pattern consistent with diagnosis, disease management/monitoring and ongoing patient care, and in palliative care, of improving quality of life through symptom management in those with diagnosed advanced diseases of many aetiologies and multiple symptoms.

Measures by setting

Primary Care

The few papers in primary care might be explained by its sheer range of clinical concerns, however, given the prevalence of breathlessness this still raises the question of a gap in clinical practice. One to two percent of primary care consultations are reported as due to breathlessness, but is likely to be an underestimate. (27-29) Around one in ten of the general population have limiting breathlessness experienced for at least three months over the past six months. (2) In people commonly attending primary care, breathlessness prevalence is much higher: about a third of older adults (30) and most with advanced chronic conditions (e.g. COPD). (4) Primary care is an excellent setting to identify, assess, manage the disease and the symptom of chronic breathlessness (30) given that most chronic condition management takes place here (31) if primary care is well developed.

The Quality and Outcomes Framework in UK primary care includes payments if a target proportion of people with COPD and mMRC ≥3 are offered pulmonary rehabilitation. (32) In this context, breathlessness is likely to be chronic, given the assumption that optimisation of COPD treatment will occur prior to or alongside pulmonary rehabilitation. However, patients with breathlessness due to other causes, e.g. heart failure, are not included in this process, and other breathlessness interventions are not mandated for those with COPD. Our included primary care studies were in the context of COPD, raising a concern that many with breathlessness due to other causes are potentially unknown, unassessed, and
unmanaged. If breathlessness is not systematically sought and assessed in primary care, then manageable suffering may go unnoticed. A recent British Lung Foundation general public online survey, “The Breath Test”, showed that a third of 365,043 respondents who were worried about their breathing (MRC grade 3 to 5) had not sought medical advice, and of those that had, 58% had not found the advice helpful.(33)

Suboptimal identification and management of breathlessness in primary care has consequences for the wider health system, especially for urgent care. Around a third of patients conveyed by ambulance to the emergency department are discharged home without hospital admission.(12) A recent systematic review found that breathlessness was the symptom general practitioners found the most difficult to address and were reluctant to prescribe opioids for severe COPD related chronic breathlessness despite its potential benefit, preferring to admit patients to hospital.(34)

Improved community-based care, including crisis plans (35) and self-management skills (36, 37), may prevent at least some urgent hospital attendance.

Secondary Care

Secondary care had the most included studies with symptom severity, impact, and cause of breathlessness measured. This is expected given that medical conditions causing breathlessness managed in this setting are common. A number of studies in this setting were from pulmonary rehabilitation services where walk tests, BORG and MRC scales (38-41), found in our included studies, are part of standard patient monitoring.(42, 43)

The pattern of measurements is consistent with the investigative, diagnostic and disease management/monitoring purpose in this setting. Most studies were in respiratory conditions such as COPD, with a few in cancer. However, breathlessness is common in other conditions such as heart disease, which has a similar clinical disease severity classification (New York Heart Association Class).(44) However, only eight studies within this setting included patient groups other than respiratory or cancer, which may indicate that breathlessness is less likely to be addressed as a clinical target in other conditions.

The importance of patient-reported outcome measures (PROMS) is increasingly recognised in oncology practice with recent work showing better patient survival when PROMS are embedded in routine practice and used in patient-clinician decision making.(45)
In general, high breathlessness NRS scores predict hospital admission from the emergency department (10-12), longer length of hospital stay, in-hospital adverse events (13, 14), and can be measured routinely.(14) However, in secondary care, other than with pulmonary rehabilitation, whilst there is evidence that breathlessness is identified and measured in COPD to inform classification of disease severity, treatment choice and to monitor response to treatment, there does not appear to be a specific clinical concern in the symptom as a therapeutic target, i.e. for chronic breathlessness. A recent cohort study of optimally treatment people with COPD estimated that just over half had chronic breathlessness syndrome with little evidence that this was being addressed.(46) This is despite the availability of evidence-based treatments or full recognition of its widespread impacts.

The revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria requires symptoms (MRC), broader impact (CAT) and exacerbations to be assessed along with spirometry, to classify stage of disease, guide COPD management and monitor progress (47). This approach could be used in other conditions.

Specialist Palliative Care

The high number of studies found in the palliative care setting reporting measures of breathlessness identification and assessment is expected in the context of a population with advanced illness receiving disease management and support with a focus on prevention, relief of suffering, and enhancement of quality of life through symptom control.(48) Unsurprisingly, diagnostic and pathophysiological tests were rarely reported although optimisation of disease treatment, and diagnosis of new conditions remain important in palliative care. However, the clinical focus of chronic breathlessness syndrome in this setting is highly likely, given that optimal treatment is usually optimised prior to a referral to palliative care.

Holistic clinical assessment is a core competency of the palliative care clinical practice curriculum (48) and forms the content of first palliative care consultations. However, implementation of standardised documentation of such assessment has been slow. Notable exceptions, such as the Palliative Care Outcome Collaborative (PCOC) in Australia, are seen. Most Australian palliative care services contribute core outcome sets for national benchmarking, using the feedback as a stimulus for service improvement, showing year on year improvement in patient report outcomes.(25) Recent initiatives, such as the Outcome
Assessment and Complexity Collaborative (OACC) – a suite of outcome measures used within palliative care to measure and improve care for patients, families and caregivers (49), derived from the PCOC, are beginning to be implemented in areas of the UK and elsewhere. A number of breathlessness measurement approaches were identified often as part of broader symptom – such as the ESAS (50-71) - or more recently as part of holistic assessments of patient concerns - such as the Patient Outcome Scale Symptom Module (POSs) (72), indicating that holistic measures may be growing.(49) Nearly half of the studies had a broad measure of performance/functional status (Appendix B). Although in the context of overall symptom assessments, breathlessness-specific quality of life impacts would not be expected, patient-reported holistic concerns were few.

Effective implementation of routine outcome measurement would be helpful to drive service improvement and provide evidence of clinically effective services for commissioners.

STRENGTHS AND LIMITATIONS

Breathlessness identification and assessment in the included studies from around the world was within the context of routine clinical practice rather than selected trial populations to provide generalisable findings. The literature was broad with robust methods to minimise selection bias. Inclusion of studies where breathlessness was measured both as a primary outcome and also as part of a full symptom assessment enabled patterns of assessment across a range of settings to be seen.

The major limitation with regard to answering our question is the use of published literature only. If health services have implemented routine identification and assessment but have not published findings, then this knowledge is unrepresented. Some healthcare settings have a stronger culture of publication than others e.g. secondary more than primary care and therefore good practice in primary care have been missed. Secondly, included papers were limited to English, and finally, most studies were either retrospective or used routine medical records with recording inaccuracies common with such designs.

Implications for clinical practice and research

In all healthcare settings, measurement of breathlessness is important because it is common, associated with poor clinical outcomes, and there are interventions which benefit
patients (73). There are clinically feasible tools available to identify and assess the wider impact of breathlessness (14) both at initial assessment, and on follow-up to assess effectiveness of interventions. The importance of breathlessness as an indicator of disease severity – as for COPD – along with a focus on breathlessness as an ongoing therapeutic target, could be incorporated in the management of other chronic conditions. Routine documented serial measurement of holistic patient concerns is important, including in services where holistic assessment is a core component of care. Systematic documentation allows benchmarking of services, illustrates service effectiveness, drives service improvement, informs service funding, and provides representative data to address clinically relevant research questions. Routine assessment of breathlessness is also required to identify chronic breathlessness syndrome, which may not be volunteered by the patient themselves.

Prospective research is needed to determine tailored-to-setting core outcome measurement sets, how best to implement core clinical outcome measures routinely in all healthcare settings, and how to use them to drive improvements in care. Use of routinely collected clinical data provides a rich source to interrogate to identify current practice gaps e.g. an analysis of England’s primary care Clinical Practice Research Database showed that lung cancer, rather than COPD, drove access to palliative care services for people with respiratory conditions highlighting an inequity in care. (74) Further trials could test if breathlessness identification and management in primary care - and first responder - based interventions will reduce inappropriate emergency hospital care. A better understanding of patient and clinician experience of identification and assessment of breathlessness particularly in the primary care setting, where it sits as one problem among many, would help inform future work.

**CONCLUSIONS**

Patterns of acute and chronic breathlessness identification and assessment vary across healthcare settings in routine clinical practice. Mostly, the patterns reflect the purpose of the health services involved but highlight missed opportunities. Firstly, primary care is well placed to seek and diagnose causes of breathlessness at an early stage and initiate and support ongoing symptom management. Secondly, routine use of simple breathlessness severity scores should be embedded into all clinical practice to identify patients in need of
evidence-based interventions. Thirdly, patient-reported measures should be used serially in all settings to monitor management and ensure that breathlessness remains a visible therapeutic target rather than a signpost to diagnosis and prognosis only.

AUTHOR CONTRIBUTIONS

HE was responsible for the design of the study, collection, and analysis of the data, and drafting and revision of the manuscript. MJ and JC supervised the project and contributed to study design, analysis and re-drafting of the paper. UN acted as second reviewer, screening records, and extracting data along with revisions to the manuscript. All authors approved the final draft.

DISCLOSURE/CONFLICTS OF INTEREST

The authors have nothing to disclose.

FUNDING

The first author is funded by a PhD scholarship from the University of Hull.
REFERENCES

1. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-52.
2. Currow DC, Plummer JL, Crockett A, Abernethy AP. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage. 2009;38(4):533-45.
3. Berliner D, Schneider N, Welte T, Bauersachs J. The Differential Diagnosis of Dyspnea. Deutsches Arzteblatt International. 2016;113(49):834-45.
4. Moens K, Higginson IJ, Harding R. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manage. 2014;48(4):660-77.
5. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliative & Supportive Care. 2003;1(4):337-44.
6. Simpson AC, Young J, Donahue M, Rocker G. A day at a time: caregiving on the edge in advanced COPD. International Journal Of Chronic Obstructive Pulmonary Disease. 2010;5:141-51.
7. Hutchinson A, Barclay-Klingel N, Galvin K, Johnson MJ. Living with breathlessness: a systematic literature review and qualitative synthesis. Eur Respir J. 2018;51(2):1701477.
8. Ekström MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. BMJ. 2015;349:g7617-g.
9. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434-40.
10. Parshall MB. Adult emergency visits for chronic cardiorespiratory disease: does dyspnea matter? Nursing Research. 1999;48(2):62-70.
11. Parshall MB, Welsh JD, Brockopp DY, et al. Dyspnea duration, distress, and intensity in emergency department visits for heart failure. Heart Lung. 2001;30(1):47-56.
12. Hutchinson A, Pickering A, Williams P, Bland JM, Johnson MJ. Breathlessness and presentation to the emergency department: a survey and clinical record review. BMC Pulmonary Medicine. 2017;17(1):53-9.
13. Stevens J, Baker K, Howell M, Banzett R. Prevalence and predictive value of dyspnea ratings in hospitalized patients: pilot studies. PLoS One. 2016;11(4):e0152601.
14. Stevens JP, Dechen T, Schwartzstein R, et al. Prevalence of dyspnea among hospitalized patients at the time of admission. J Pain Symptom Manage Management. 2018.
15. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017;49(5):1-8.
16. Hopkinson NS, Baxter N. Breathing SPACE—a practical approach to the breathless patient. npj Primary Care Respiratory Medicine. 2017;27(1):1-5.
17. Spithis A, Booth S, Moffat C, et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. npj Primary Care Respiratory Medicine. 2017;27:1-6.
18. Johnson MJ, Currow DC, Booth S. Prevalence and assessment of breathlessness in the clinical setting. Expert Review of Respiratory Medicine. 2014;8(2):151-61.
19. Gysels M, Higginson IJ. Access to services for patients with chronic obstructive pulmonary disease: the invisibility of breathlessness. J Pain Symptom Manage. 2008;36(5):451-60.
20. Currow DC, Johnson MJ. Chronic breathlessness: silent and deadly. Current Opinion in Supportive and Palliative Care. 2016;10(3):221-2.
21. Carel H, Macnaughton J, Dodd J. Invisible suffering: breathlessness in and beyond the clinic. The Lancet Respiratory Medicine. 2015;3(4):278-9.
22. Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the clinical rather than the research setting. Current Opinion in Supportive and Palliative Care. 2008;2(2):95-9.
23. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: A systematic review. Respir Med. 2007;101(3):399-410.
24. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med. 2007;21(3):177-91.
25. Currow DC, Allingham S, Yates P, et al. Improving national hospice/palliative care service symptom outcomes systematically through point-of-care data collection, structured feedback and benchmarking. Support Care Cancer. 2015;23(2):307-15.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:1-8.
27. Currow DC, Clark K, Mitchell GK, Johnson MJ, Abernethy AP. Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. Plos One. 2013;8(9):e74814-e.
28. Frese T, Sobeck C, Herrmann K, Sandholzer H. Dyspnea as the reason for encounter in general practice. Journal Of Clinical Medicine Research. 2011;3(5):239-46.
29. von Winckelmann K, Renier W, Thompson M, Buntinx F. The frequency and outcome of acute dyspnoea in primary care: An observational study. European Journal of General Practice. 2016;22(4):240-6.
30. Baxter N. Breathlessness in the primary care setting. Current Opinion In Supportive And Palliative Care. 2017;11(3):152-8.
31. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respiratory Research. 2008;9(1):62.
32. NHS England. A five-year framework for GP contract reform to implement The NHS Long Term Plan. England 2019 [Available from: https://www.england.nhs.uk/publication/gp-contract-five-year-framework/.
33. Elbehairy A, Quint J, Rogers J, et al. Patterns of breathlessness in the UK: results from the British Lung Foundation online breath test. Thorax; 2018.
34. Mitchell GK, Senior HE, Johnson CE, et al. Systematic review of general practice end-of-life symptom control. BMJ Supportive & Palliative Care. 2018;8(4):411-20.
35. Mularski RA, Reinke LF, Carriere-Kohlman V, et al. An official American Thoracic Society workshop report: assessment and palliative management of dyspnea crisis. Annals of the American Thoracic Society. 2013;10(5):598-5106.
36. Luckett T, Phillips J, Johnson MJ, et al. Contributions of a hand-held fan to self-management of chronic breathlessness. Eur Respir J. 2017;50(2).
37. Luckett T, Phillips J, Johnson M, et al. Insights from Australians with respiratory disease living in the community with experience of self-managing through an emergency department ‘near miss’ for breathlessness: a strengths-based qualitative study. BMJ Open. 2017;7(12):e017536.
38. Greulich T, Koczulla AR, Nell C, et al. Effect of a three-week inpatient rehabilitation program on 544 consecutive patients with very severe COPD: a retrospective analysis. Respiration. 2015;90(4):287-92.
39. Tramacere A, Rizzardi R, Cilione C, et al. Effects of respiratory therapist-directed protocol on prescription and outcomes of pulmonary rehabilitation in COPD inpatients. Respiration. 2004;71(1):60-5.
40. Clini EM, Crisafulli E, Costi S, et al. Effects of early inpatient rehabilitation after acute exacerbation of COPD. Respir Med. 2009;103(10):1526-31.
41. Johnson-Warrington V, Sewell L, Morgan M, Singh S. Do we need a practice incremental shuttle walk test for patients with interstitial lung disease referred for pulmonary rehabilitation? Respirology. 2015;20(3):434-8.
42. Zeng Y, Jiang F, Chen Y, Chen P, Cai S. Exercise assessments and trainings of pulmonary rehabilitation in COPD: a literature review. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:2013.
43. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13-e64.
44. Gysels MH, Higginson IJ. The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND. BMC Palliative Care. 2011;10(1):15.
45. Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of patient-reported outcomes in routine medical care. American Society of Clinical Oncology Educational Book. 2018;38:122-34.
46. Carette H, Zysman M, Morelot-Panzini C, et al. Prevalence and management of chronic breathlessness in COPD in a tertiary care center. BMC Pulmonary Medicine. 2019;19(1):95.
47. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557-82.
48. World Health Organisation. Integrating palliative care and symptom relief into primary health care: a WHO guide for planners, implementers and managers. Geneva: World Health Organisation; 2018.
49. Witt J, Murtagh F, de Wolf-Linder S, Higginson I, Daveson B. Introducing the Outcome Assessment and Complexity Collaborative (OACC) Suite of Measures-A Brief Introduction. Kings College London. 2014.
50. Burton A, Mendoza T, Gebhardt R, et al. Vertebral Compression Fracture Treatment with Vertebroplasty and Kyphoplasty: Experience in 407 Patients with 1,156 Fractures in a Tertiary Cancer Center. Pain Medicine. 2011;12(12):1750-7.
51. Cameron P, Ellis P, Pond G, Goffin J. Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis. Palliat Med. 2012;26(6):797-803.
52. Eades M, Murphy J, Carney S, et al. Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: Review of clinical experience. Head Neck. 2013;35(3):343-9.
53. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? an audit after implementing electronic symptom screening. Journal of Oncology Practice. 2012;8(6):e142-e8.
54. Bostwick D, Wolf S, Samsa G, et al. Comparing the Palliative Care Needs of Those With Cancer to Those With Common Non-Cancer Serious Illness. J Pain Symptom Manage. 2017;53(6):1079-84.e1.
55. Cheung W, Barmala N, Zarinehba S, et al. The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage. 2009;37(3):297-304.
56. Cheung W, Le L, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer. 2009;17(9):1223-30.
57. Covarrubias-Gómez A, Hernández-Martínez E, Ruiz-Ramírez S, López Collada-Estrada M. Assessment of Pain and Other Symptoms in Mexican Patients With Advanced Illness. Journal of Pain & Palliative Care Pharmacotherapy. 2014;28(4):394-8.
58. de la Cruz M, Fan J, Yennu S, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer. 2015;23(8):2427-33.
59. Delgado-Guay M, Rodriguez-Nunez A, Shin S, et al. Characteristics and outcomes of patients with advanced cancer evaluated by a palliative care team at an emergency center. A retrospective study. Support Care Cancer. 2016;24(5):2287-95.
60. Ekström M, Allingham S, Eagar K, et al. Breathlessness During the Last Week of Life in Palliative Care: An Australian Prospective, Longitudinal Study. J Pain Symptom Manage. 2016;51(5):816-23.
61. Kang J, Kwon J, Hui D, Yennurajalingam S, Bruera E. Changes in symptom intensity among cancer patients receiving outpatient palliative care. J Pain Symptom Manage. 2013;46(5):652-60.
62. Lefkowits C, Teuteberg W, Courtney-Brooks M, et al. Improvement in symptom burden within one day after palliative care consultation in a cohort of gynecologic oncology inpatients. Gynecol Oncol. 2015;136(3):424-8.
63. Mercadante S, Degiovanni D, Casuccio A. Symptom burden in mesothelioma patients admitted to home palliative care. Curr Med Res Opin. 2016;32(12):1985-8.
64. Olson K, Hayduk L, Cree M, et al. The changing causal foundations of cancer-related symptom clustering during the final month of palliative care: a longitudinal study. BMC Medical Research Methodology. 2008;8:36-.
65. Parsons H, Delgado-Guay M, El Osta B, et al. Alcoholism screening in patients with advanced cancer: Impact on symptom burden and opioid use. Journal of Palliative Medicine. 2008;11(7):964-8.
66. Cuervo Pinna M, Mota Vargas R, Redondo Moralo M, Sánchez Correas M, Pera Blanco G. Dyspnea--a bad prognosis symptom at the end of life. American Journal of Hospice & Palliative Medicine. 2009;26(2):89-97.
67. Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, et al. Is Early Palliative Care Feasible in Patients With Multiple Myeloma? J Pain Symptom Manage. 2017;54(5):692-700.
68. Porzio G, Ricevuto E, Aielli F, et al. The Supportive Care Task Force at the University of L'Aquila: 2-Years experience. Support Care Cancer. 2005;13(6):351-5.
69. Shin S, Hui D, Chisholm G, et al. Characteristics and outcomes of patients admitted to the acute palliative care unit from the emergency center. J Pain Symptom Manage. 2014;47(6):1028-34.
70. Strasser F, Sweeney C, Willey J, et al. Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on
recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 2004;27(6):481-91.

71. Yennurajalingam S, Kwon J, Urbauer D, et al. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. Palliative & Supportive Care. 2013;11(6):473-80.

72. Murphy E, Murtagh F, Carey I, Sheerin N. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: Use of a short patient-completed assessment tool. Nephron Clinical Practice. 2009;111(1):c74-c80.

73. Stevens J, Baker K, Howell M, Banzett R. Prevalence and predictive value of dyspnea ratings in hospitalized patients: Pilot studies. PLoS ONE. 2016;11(4):e0152601.

74. Bloom CI, Slaich B, Morales DR, et al. Low uptake of palliative care for COPD patients within primary care in the UK. Eur Respir J. 2018;51(2):1701879.
## APPENDIX A - DIFFERENT TYPES OF BREATHLESSNESS ASSESSMENT MEASURES

| Symptom severity measures of breathlessness: Tools n=17, Studies n=70 | Measures of the impact of breathlessness (on wider factors): Tools n=20, Studies n=55 | Measures of the cause/diagnosis of breathlessness: Tools n=12, Studies n=47 |
|---|---|---|
| **BDI/TDI** | **BDI/TDI** | Bronchoscopy |
| **BORG Scales** | **BORG Scales** | CTS |
| Categorical scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) | BPQ | Doppler echocardiography (2D) |
| **ESAS Scales** | CAT (COPD) | ECG (Electrocardiogram) |
| **McCorkle Symptom Distress Scale** | CCQ (COPD) | Echocardiogram |
| **MDASI** | **MDASI** | High sensitive C-reactive protein |
| **NRS** | CRQ (Chronic Respiratory Diseases) | Imaging (CT, MRI, Chest X-Ray, HRCT) |
| **Patient Outcome Scale Symptom Module** | Functional Capacity Scale | LFM |
| **Quantitative Scale** | KPS Scales | VATS |
| **Respiratory symptom scales (adapted from MRC and RSQ)** | **NYHA** | **NYHA** |
| **Van Den Bongard's Score (none (0), slight (1), severe (2) and high-grade stenosis with cyanosis or stridor (3))** | LINQ | Van Den Bongard's Score (none (0), slight (1), severe (2) and high-grade stenosis with cyanosis or stridor (3)) |
| **MRC Scales** | **MRC Scales** | Waveform capnography (ETCO2) |
| **SAS** | Palliative Care Assessment Tool | |
| **Unknown - dyspnea assessed** | Palliative Prognostic Score | |
| **UCSD** | **UCSD** | |
| **VAS** | Palliative Performance Scale | |
| **Rotterdam symptom checklist** | **Rotterdam symptom checklist** | |
| | SGRQ (Respiratory Diseases) | |
| | STAS (Schedule for Team Assessment) | |
| | Walk tests | |
BDI/TDI: Baseline and Transition Dyspnea Index; Borg Scales (Borg, MBS, Borg RPE); BPQ: Breathing Problems Questionnaire; CAT: COPD Assessment Test; CTS: Canadian Thoracic Screening Questionnaire; CCQ: Clinical COPD Questionnaire; CRQ: Chronic Respiratory Disease Questionnaire; ESAS: Edmonton Symptom Assessment Scale (ESAS; Modified ESAS); KPS: Karnofsky Performance Status (Karnofsky Performance Status; Australian modified Karnofsky Performance Status); LINQ: Lung Information Needs Questionnaire; LFM: Lung Function Measurements; MDASI: MD Anderson Symptom Inventory; MRC: Medical Research Council Dyspnea Scale (MRC, mMRC, emRC); NRS: Numerical Rating Scale; NYHA: New York Heart Association Functional Classification; SAS: Symptom Assessment Scale; SGRQ: St. George’s Respiratory Questionnaire; STAS: Schedule for Team Assessment; UCSD: University of California San Diego Shortness of Breath Questionnaire; VATS: Video Assisted Thoracic Surgery; VAS: Visual Analogue Scale; Walk tests (ESWT; ISWT, 6MWD, 6MWT, Shuttle/Treadmill Walk Test).

*Italics are used if measures are found in more than one category.*
## APPENDIX B – DIFFERENT TYPES OF BREATHLESSNESS IDENTIFICATION AND ASSESSMENT MEASURES ACROSS HEALTH CARE SETTINGS

| Symptom severity measures of breathlessness: Tools n=17, Studies n=70 | Primary care | Secondary Care | SPC | Total |
|------------------------------------------------|--------------|----------------|-----|-------|
| Medical Research Council Dyspnoea Scales*1 | 6            | 21             | n=27|
| Edmonton Symptom Assessment Scales*2        | 4            | 18             | n=22|
| BORG*3                                      |              | 13             | n=13|
| Visual Analogue Scale*                      | 1            | 3              | n=4 |
| University of California San Diego Shortness of Breath Questionnaire* | 3 | | n=3 |
| McCorkle Symptom Distress Scale*            | 2            |                | n=2 |
| Symptom Assessment Scale*                   | 2            |                | n=2 |
| Baseline and Transition Dyspnoea Index*     | 1            |                | n=1 |
| Categorical scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)* | 1 | | n=1 |
| MD Anderson Symptom Inventory*              | 1            |                | n=1 |
| Numerical Rating Scale*                     | 1            |                | n=1 |
| Patient Outcome Scale Symptom Module*      | 1            |                | n=1 |
| Quantitative Scale                          | 1            |                | n=1 |
| Respiratory symptom scales (adapted from the MRC Respiratory Symptoms Questionnaire and Dyspnoea Scale* | | 1 | n=1 |
| Rotterdam symptom checklist*                |              |                | n=1 |
| Unknown - dyspnea assessed                  | 1            |                | n=1 |
| Van Den Bongard’s Score (none (0), slight (1), severe (2) and high-grade stenosis with cyanosis or stridor (3))* | | 1 | n=1 |
| **Total number of measures used**          | n=6          | n=48           | n=29| n=83  |
| **Total number of distinct measures**       | n=1          | n=11           | n=8 | n=20  |
| **Total number of studies using measures of severity of breathlessness** | n=6 | n=38 | n=26 | n=70 |
| **Number of studies as a proportion of total (97) studies** | 6.2% | 39.2% | 26.8% |

| Measures of the impact of breathlessness (on wider factors): Tools n=20, Studies n=55 | Primary care | Secondary Care | SPC |
|--------------------------------------------------------------------------------------------|--------------|----------------|-----|
| Medical Research Council Dyspnoea Scales*1                                                 | 6            | 21             | n=27|
| Walk tests*                                                                                 |              | 19             | n=19|
| BORG*3                                                                                      | 13           |                | n=13|
| COPD Assessment Test*                                                                       | 2            | 4              | n=7 |
| St. Georges Respiratory Questionnaire*                                                       | 7            |                | n=7 |
| KPS Scales*                                                                                 | 6            |                | n=6 |
| Palliative Performance Scale                                                                | 4            |                | n=4 |
| Measure                                                                 | Primary Care | Secondary Care | SPC |
|-----------------------------------------------------------------------|--------------|----------------|-----|
| University of California San Diego Shortness of Breath Questionnaire* | 3            | n=3            |     |
| Chronic Respiratory Diseases Questionnaire                           | 2            | n=2            |     |
| New York Heart Association Functional Classification                 | 2            | n=2            |     |
| Palliative Prognostic Score                                          | 2            | n=2            |     |
| Schedule for Team Assessment                                          | 2            | n=2            |     |
| Baseline and Transition Dyspnoea Index*                              | 1            | n=1            |     |
| Breathing Problems Questionnaire                                      | 1            | n=1            |     |
| Clinical COPD Questionnaire*                                          | 1            | n=1            |     |
| Functional Capacity Scale                                            | 1            | n=1            |     |
| Lung Information Needs Questionnaire                                  | 1            | n=1            |     |
| MD Anderson Symptom Inventory*                                        | 1            | n=1            |     |
| Palliative Care Assessment Tool*                                      | 1            | n=1            |     |
| Rotterdam symptom checklist*                                          | 1            | n=1            |     |

Total number of measures used: 
- n=10
- n=74
- n=18
- n=102

Total number of distinct measures: 
- n=4
- n=11
- n=8
- n=23

Total number of studies using impact measures of breathlessness: 
- n=6
- n=33
- n=16
- n=55

Number of studies as a proportion of total (97) studies: 
- 6.2%
- 34.0%
- 16.5%

Measures of the cause/diagnosis of breathlessness: Tools n=12, Studies n=47

| Measure                                                                 | Primary Care | Secondary Care | SPC |
|-----------------------------------------------------------------------|--------------|----------------|-----|
| Lung Function Measurements<sup>6</sup>                                | 8            | 30             | 3 n=41|
| Imaging (CT, MRI, Chest X-Ray, HRCT)                                  | 5            | n=5            |     |
| New York Heart Association Functional Classification                  | 2            | n=2            |     |
| Bronchoscopy                                                          | 1            | n=1            |     |
| Canadian Thoracic Society Screening Questions*                         | 1            | n=1            |     |
| Doppler echocardiography (2D)                                         | 1            | n=1            |     |
| ECG (Electrocardiogram)                                               | 1            | n=1            |     |
| Echocardiogram                                                        | 1            | n=1            |     |
| High sensitive C-reactive protein                                     | 1            | n=1            |     |
| Van Den Bongard’s Score (none (0), slight (1), severe (2) and high-grade stenosis with cyanosis or stridor (3))<sup>*</sup> | 1            | n=1            |     |
| Video Assisted Thoracic Surgery                                       | 1            | n=1            |     |
| Waveform capnography (ETCO2)                                          | 1            | n=1            |     |

Total number of studies using cause/diagnosis measures of breathlessness: 
- n=9
- n=45
- n=3
- n=57

Total number of distinct measures: 
- n=2
- n=11
- n=1
- n=14

Number of studies as a proportion of total (97) studies: 
- 8.2%
- 37.1%
- 3.1%

<sup>2</sup> Includes MRC, mMRC (modified mRC) and eMRC (extended MRC).
Includes ESAS and Modified ESAS.

Includes BORG, Modified BORG and BORG RPE (Rate of Perceived Exertion).

Includes 6MWD (6 minute walk distance), 6MWT (6 minute walk test), ESWT (Endurance Shuttle Walk Test), ISWT (Incremental Shuttle Walk Test), Shuttle Walk Test and Treadmill Walk Test.

Includes KPS and AKPS.

Includes FEV1, FEV% pred, FEV1%, FEV1% pred, FVC, FVC%, FVC% pred, FEV/FVC, FEV1/FVC, FEV1/FVC%, FEV1/VC, FEV1/VC%, VC, VC% pred, TLC, TLC%, TLC% pred, TLCO, TLCO% pred, DLCO, DLCO%, DLCO% pred, DLCO/VA%, KCO% pred, RV, RV% pred, RV/TLC, RV/TLC%, RV/TLC% pred, FRC% pred, IC% pred, IC/TLC%, PaO2, PaCO2, pH, PEFR, SaO2, SO2, SpO2, MIP, MEP, MVV% pred.

* Measures used for both identification and assessment

* Italics are used if measures are found in more than one category.
1. Haughney J, Gruffydd-Jones K, Roberts J, et al. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J. 2014;43(4):993-1002.

2. Merinopoulou E, Raluy-Callado M, Ramagopalan S, Maclachlan S, Khalid JM. COPD exacerbations by disease severity in England. International Journal of COPD. 2016;11(1):697-709.

3. Nibber A, Chisholm A, Soler-Cataluna J, et al. Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2017;14(5):504-12.

4. van den Bemt L, Smeele I, Kolkman M, et al. Low body mass index, airflow obstruction, and dyspnoea in a primary care COPD patient population. Primary Care Respiratory Journal. 2010;19(2):118-23.

5. Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS ONE. 2014;9(1):e85540.

6. Jones R, Dickson-Spillmann M, Mather M, Marks D, Shackell B. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respiratory Research. 2008;9:62-.

7. Lee L, Patel T, Hillier L, Milligan J. Office-Based Case Finding for Chronic Obstructive Pulmonary Disease in Older Adults in Primary Care. Canadian Respiratory Journal. 2016;2016:1083270.

8. Singh MP. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: Findings from a single-center primary care cohort. International Journal of Chronic Obstructive Pulmonary Disease. 2013;8:613-9.

9. Steer J, Norman E, Afolabi O, Gibson G, Bourke S. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2):117-21.

10. Morris D, Galicia-Castillo M. Dying With Dyspnea in the Hospital. American Journal of Hospice & Palliative Medicine. 2017;34(2):132-4.

11. Webb M, Moody L, Mason L. Dyspnea assessment and management in hospice patients with pulmonary disorders. American Journal of Hospice & Palliative Medicine. 2000;17(4):259-64.

12. Manali E, Stathopoulos G, Kollintza A, et al. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med. 2008;102(4):586-92.

13. Ekström M, Allingham S, Eagar K, et al. Breathlessness During the Last Week of Life in Palliative Care: An Australian Prospective, Longitudinal Study. J Pain Symptom Manage. 2016;51(5):816-23.

14. Cameron P, Ellis P, Pond G, Goffin J. Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis. Palliat Med. 2012;26(6):797-803.

15. Kendrick K, Baxi S, Smith R. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. Journal of Emergency Nursing. 2000;26(3):216-88.

16. Rozenberg D, Leek E, Faughnan M. Prevalence and nature of dyspnea in patients with hereditary hemorrhagic telangiectasia (HHT). Respir Med. 2015;109(6):768-77.
17. Banerjee D, Kamuren J, Baird G, et al. The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulmonary Circulation. 2017;7(2):384-90.

18. Cuervo Pinna M, Mota Vargas R, Redondo Moralo M, Sánchez Correas M, Pera Blanco G. Dyspnea—a bad prognosis symptom at the end of life. American Journal of Hospice & Palliative Medicine. 2009;26(2):89-97.

19. Hately J, Laurence V, Scott A, Baker R, Thomas P. Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer. Palliat Med. 2003;17(4):410-7.

20. Gomutbutra P, O'Riordan D, Pantilat S. Management of Moderate-to-Severe Dyspnea in Hospitalized Patients Receiving Palliative Care. J Pain Symptom Manage. 2013;45(5):885-91.

21. Greulich T, Koczulla A, Nell C, et al. Effect of a Three-Week Inpatient Rehabilitation Program on 544 Consecutive Patients with Very Severe COPD: A Retrospective Analysis. Respiration. 2015;90(4):287-92.

22. Wu J, Lee K, Dekker R, et al. Prehospital Delay, Precipitants of Admission, and Length of Stay in Patients With Exacerbation of Heart Failure. Am J Crit Care. 2016;26(1):62-9.

23. Yennurajalingam S, Kwon J, Urbauer D, et al. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. Palliative & Supportive Care. 2013;11(6):473-80.

24. Franssen F, Spruit M, Wouters E. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2011;6:493-501.

25. Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, et al. Is Early Palliative Care Feasible in Patients With Multiple Myeloma? J Pain Symptom Manage. 2017;54(5):692-700.

26. Kang J, Kwon J, Hui D, Yennurajalingam S, Bruera E. Changes in symptom intensity among cancer patients receiving outpatient palliative care. J Pain Symptom Manage. 2013;46(5):652-60.

27. Cheung W, Barmala N, Zarinehbaf S, et al. The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manage. 2009;37(3):297-304.

28. Ferreira A, Garvey C, Connors G, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135(2):442-7.

29. Shin S, Hui D, Chisholm G, et al. Characteristics and outcomes of patients admitted to the acute palliative care unit from the emergency center. J Pain Symptom Manage. 2014;47(6):1028-34.

30. Mercadante S, Degiovanni D, Casuccio A. Symptom burden in mesothelioma patients admitted to home palliative care. Curr Med Res Opin. 2016;32(12):1985-8.

31. Parsons H, Delgado-Guay M, El Osta B, et al. Alcoholism screening in patients with advanced cancer: Impact on symptom burden and opioid use. Journal of Palliative Medicine. 2008;11(7):964-8.

32. Nishizaki Y, Daimon M, Miyazaki S, et al. Clinical factors associated with classical symptoms of aortic valve stenosis. J Heart Valve Dis. 2013;22(3):287-94.

33. Ryan A, Carter J, Lucas J, Berger J. You need not make the journey alone: overcoming impediments to providing palliative care in a public urban teaching hospital. American Journal of Hospice & Palliative Care. 2002;19(3):171-1p.
34. Zanini A, Aiello M, Adamo D, et al. Effects of Pulmonary Rehabilitation in Patients with Non-Cystic Fibrosis Bronchiectasis: A Retrospective Analysis of Clinical and Functional Predictors of Efficacy. Respiration. 2015;89(6):525-33.
35. Lange P, Andersen K, Munch E, et al. Quality of COPD care in hospital outpatient clinics in Denmark: The KOLIBRI study. Respir Med. 2009;103(11):1657-62.
36. Miyahara S, Nakai H, Izawa N, et al. Influences of chronic obstructive pulmonary disease on outcomes of total arch replacement. Ann Thorac Surg. 2015;99(1):72-8.
37. Bajwah S, Higginson I, Ross J, et al. Specialist palliative care is more than drugs: A retrospective study of ILD Patients. Lung. 2012;190(2):215-20.
38. Murphy E, Murtagh F, Carey I, Sheerin N. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: Use of a short patient-completed assessment tool. Nephron Clinical Practice. 2009;111(1):c74-c80.
39. Bagheri R, Haghi S, Attaran D, et al. Efficacy of minimally invasive surgery in diagnosis of interstitial lung disease. Asian Cardiovascular and Thoracic Annals. 2015;23(7):851-4.
40. Cheng Y, Tu X, Pan L, et al. Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:2069-74.
41. Mapel D, McMillan G, Frost F, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med. 2005;99(10):1325-33.
42. Wysham N, Cox C, Wolf S, Kamal A. Symptom Burden of Chronic Lung Disease Compared with Lung Cancer at Time of Referral for Palliative Care Consultation. Annals of the American Thoracic Society. 2015;12(9):1294-301.
43. Vanfleteren L, Franssen F, Uszko-Lencer N, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol. 2011;108(11):1669-74.
44. Cheung W, Le L, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer. 2009;17(9):1223-30.
45. Thaiss W, Nikolaou K, Spengler W, et al. Imaging diagnosis in relapsing polychondritis and correlation with clinical and serological data. Skeletal Radiol. 2016;45(3):339-46.
46. Pang G, Qu L, Wong Y, et al. A Quantitative Framework Classifying the Palliative Care Workforce into Specialist and Generalist Components. Journal of Palliative Medicine. 2015;18(12):1063-9.
47. Mancini I, Lossignol D, Obiols M, et al. Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer. 2002;10(1):3-7.
48. Morris G, Gallagher G, Baxter M, et al. Pulmonary rehabilitation improves functional status in oncology patients. Arch Phys Med Rehabil. 2009;90(5):837-41.
49. Kelly J, Bamsey O, Smith C, et al. Health Status Assessment in Routine Clinical Practice: The Chronic Obstructive Pulmonary Disease Assessment Test Score in Outpatients. Respiration. 2012;84(3):193-9.
50. Kontogianni K, Gerovasili V, Gompelmann D, et al. Effectiveness of endobronchial coil treatment for lung volume reduction in patients with severe heterogeneous emphysema and bilateral incomplete fissures: A six-month follow-up. Respiration. 2014;88(1):52-60.
51. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? an audit after implementing electronic symptom screening. Journal of Oncology Practice. 2012;8(6):e142-e8.
52. Schroedl C, Yount S, Szmuilowicz E, Rosenberg S, Kalhan R. Outpatient palliative care for chronic obstructive pulmonary disease: A case series. Journal of Palliative Medicine. 2014;17(11):1256-61.
53. Kavalieratos D, Arif H, Abernethy A, et al. Comparing Unmet Needs between Community-Based Palliative Care Patients with Heart Failure and Patients with Cancer. Journal of Palliative Medicine. 2014;17(4):475-81.
54. Lefkowits C, Teuteberg W, Courtney-Brooks M, et al. Improvement in symptom burden within one day after palliative care consultation in a cohort of gynecologic oncology inpatients. Gynecol Oncol. 2015;136(3):424-8.
55. Evangelista L, Dracup K, Doering L. Treatment-seeking delays in heart failure patients. J Heart Lung Transplant. 2000;19(10):932-8.
56. Delgado-Guay M, Rodriguez-Nunez A, Shin S, et al. Characteristics and outcomes of patients with advanced cancer evaluated by a palliative care team at an emergency center. A retrospective study. Support Care Cancer. 2016;24(5):2287-95.
57. Bostwick D, Wolf S, Samsa G, et al. Comparing the Palliative Care Needs of Those With Cancer to Those With Common Non-Cancer Serious Illness. J Pain Symptom Manage. 2017;53(6):1079-84.e1.
58. Covarrubias-Gómez A, Hernández-Martínez E, Ruiz-Ramírez S, López Collada-Estrada M. Assessment of Pain and Other Symptoms in Mexican Patients With Advanced Illness. Journal of Pain & Palliative Care Pharmacotherapy. 2014;28(4):394-8.
59. Hall P, Schroder C, Weaver L. The last 48 hours of life in long-term care: a focused chart audit. J Am Geriatr Soc. 2002;50(3):501-6.
60. Revill S, Williams J, Sewell L, Collier R, Singh S. Within-day repeatability of the endurance shuttle walk test. Physiotherapy. 2009;95(2):140-3.
61. Calle Rubio M, Lopez-Campos J, Soler-Cataluna J, et al. Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: A multi-level, cross-sectional analysis of the EPOCONSUL study. Respiratory Research. 2017;18(1):200.
62. Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2001;18(6):903-8.
63. Major S, Moreno M, Shelton J, Panos R. Veterans with chronic obstructive pulmonary disease achieve clinically relevant improvements in respiratory health after pulmonary rehabilitation. Journal of Cardiopulmonary Rehabilitation & Prevention. 2014;34(6):420-9.
64. Tramacere A, Rizzardi R, Cilione C, et al. Effects of Respiratory Therapist-Directed Protocol on Prescription and Outcomes of Pulmonary Rehabilitation in COPD Inpatients. Respiration. 2004;71(1):60-5.
65. Olson K, Hayduk L, Cree M, et al. The changing causal foundations of cancer-related symptom clustering during the final month of palliative care: a longitudinal study. BMC Medical Research Methodology. 2008;8:36-.
66. Ernst A, Rafeq S, Boiselle P, et al. Relapsing polychondritis and airway involvement. Chest. 2009;135(4):1024-30.
67. Porzio G, Ricevuto E, Aielli F, et al. The Supportive Care Task Force at the University of L'Aquila: 2-Years experience. Support Care Cancer. 2005;13(6):351-5.
68. Caraceni A, Zecca E, Martini C, et al. Palliative sedation at the end of life at a tertiary cancer center. Support Care Cancer. 2012;20(6):1299-307.
69. Twaddle M, Maxwell T, Cassel J, et al. Palliative care benchmarks from academic medical centers. Journal of Palliative Medicine. 2007;10(1):86-98.
70. Burton A, Mendoza T, Gebhardt R, et al. Vertebral Compression Fracture Treatment with Vertebroplasty and Kyphoplasty: Experience in 407 Patients with 1,156 Fractures in a Tertiary Cancer Center. Pain Medicine. 2011;12(12):1750-7.
71. Zhang J, Lin X, Bai C. Comparison of clinical features between non-smokers with copd and smokers with copd: A retrospective observational study. International Journal of Chronic Obstructive Pulmonary Disease. 2014;9:57-63.
72. Bailey S, Brown L, Bailey E. Lack of relationship between functional and perceived quality of life outcomes following pulmonary rehabilitation. Cardiopulmonary Physical Therapy Journal. 2008;19(1):3-10.
73. Pierie J, Muzikansky A, Gaz R, Faquin W, Ott M. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9(1):57-64.
74. Kaymaz D, Ergun P, Candemir I, et al. Pulmonary rehabilitation in interstitial lung diseases. Tuberkuloz ve Toraks. 2013;61(4):295-302.
75. Walling A, Asch S, Lorenz K, et al. The quality of supportive care among inpatients dying with advanced cancer. Support Care Cancer. 2012;20(9):2189-94.
76. Bourke S, Booth Z, Doe S, et al. A service evaluation of an integrated model of palliative care of cystic fibrosis. Palliat Med. 2016;30(7):698-702.
77. Clini E, Crisafulli E, Costi S, et al. Effects of early inpatient rehabilitation after acute exacerbation of COPD. Respir Med. 2009;103(10):1526-31.
78. Connor M, O'Shea F, O'Driscoll M, Concannon D, McDonnell T. Efficacy of pulmonary rehabilitation in an Irish population. Ir Med J. 2001;94(2):46-8.
79. Morita T, Fujimoto K, Tei Y. Palliative care team: the first year audit in Japan. J Pain Symptom Manage. 2005;29(5):458-65.
80. Abela J. Symptom management by a community palliative care team. Malta Medical Journal. 2009;21(4):12-8.
81. Eades M, Murphy J, Carney S, et al. Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: Review of clinical experience. Head Neck. 2013;35(3):343-9.
82. de la Cruz M, Fan J, Yennu S, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer. 2015;23(8):2427-33.
83. Freeman S, Hirdes J, Stolee P, et al. Care planning needs of palliative home care clients: Development of the interRAI palliative care assessment clinical assessment protocols (CAPs). BMC Palliative Care. 2014;13(1):58.
84. Strasser F, Sweeney C, Willey J, et al. Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 2004;27(6):481-91.
85. Majewski M, Rozek K, Alawale O. Ambulatory pulmonary rehabilitation programme in patients suffering from chronic obstructive pulmonary disease (COPD): A preliminary study. [Polish, English]. Fizjoterapia. 2010;18(4):11-20.
86. Walling A, Tisnado D, Asch S, et al. The quality of supportive cancer care in the veterans affairs health system and targets for improvement. JAMA Internal Medicine. 2013;173(22):2071-9.
87. Cowan J, Walsh D, Homsi J. Palliative medicine in a United States cancer center: a prospective study. American Journal of Hospice & Palliative Care. 2002;19(4):240-1p.
88. Leclere S, Antonietti M, Di Fiore F, et al. Double stenting of oesophagus and airways in palliative treatment of patients with oesophageal cancer is efficient but associated with a high morbidity. Aliment Pharmacol Ther. 2007;25(8):955-63.
89. Johnson-Warrington V, Sewell L, Morgan M, Singh S. Do we need a practice incremental shuttle walk test for patients with interstitial lung disease referred for pulmonary rehabilitation? Respirology. 2015;20(3):434-8.
90. Tottenborg S, Thomsen R, Nielsen H, et al. Improving quality of care among COPD outpatients in Denmark 2008-2011. Clinical Respiratory Journal. 2013;7(4):319-27.
91. Wysham N, Hochman M, Wolf S, Cox C, Kamal A. Performance of Consultative Palliative Care Model in Achieving Quality Metrics in the ICU. J Pain Symptom Manage. 2016;52(6):873-7.
92. Malin J, O'Neill S, Asch S, et al. Quality of Supportive Care for Patients with Advanced Cancer in a VA Medical Center. Journal of Palliative Medicine. 2011;14(5):573-7.
93. Walling A, Asch S, Lorenz K, et al. The quality of care provided to hospitalized patients at the end of life. Arch Intern Med. 2010;170(12):1057-63.
94. Hunter C, Silvestri S, Ralls G, Papa L. Prehospital end-tidal carbon dioxide differentiates between cardiac and obstructive causes of dyspnoea. Emergency Medicine Journal. 2015;32(6):453-6.
95. Bruera E, Schmitz B, Pither J, Neumann C, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2000;19(5):357-62.
96. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(5):1067-72.
97. Stevens J, Dechen T, Schwartzstein R, et al. Prevalence of dyspnea among hospitalized patients at the time of admission. J Pain Symptom Manage. 2018;56(1):15-22. e2.
### Table 1: Inclusion and Exclusion Criteria

| Inclusion                                                                 |
|---------------------------------------------------------------------------|
| • All observational quantitative and qualitative study designs (that use  |
| routinely collected data within the context of routine clinical practice  |
| (primary, secondary, emergency), for example service evaluations, clinical |
| audits, chart reviews, or similar)                                         |
| • Primary research                                                        |
| • Any health setting (e.g. primary care, secondary care, community care). |
| • Studies published since 2000                                            |
| • Adults (18+) with breathlessness (studies including adults and children |
| were included if the adult population data can be adequately extracted)   |
| • Adults with breathlessness due to any chronic illness or disease (apart |
| from those listed in the exclusion criteria; studies that have any of these |
| included conditions along with any ‘chronic illness or disease’ only     |
| included if the ‘chronic illness or disease’ data can be adequately       |
| extracted)                                                                |

| Exclusion                                                                 |
|---------------------------------------------------------------------------|
| • Case histories, commentaries, opinion pieces, conferences presentations, |
| and other grey literature                                                  |
| • Systematic reviews                                                      |
| • Experimental studies (Randomised Controlled Trials (RCT), quasi-         |
| experimental) for example, interventions of breathlessness assessments/    |
| measures or of breathlessness treatments were excluded                    |
| • Anything not applied in routine clinical practice                       |
| • Studies including children and/or animals                                |
| • Studies not in the English Language.                                    |
| • Healthy adults with induced-breathlessness (e.g. recreational exercise, |
| sports, exercise laboratory)                                              |
| • Adults with asthma (specific pathophysiology, treatment pathways and its |
| own literature), hyperventilation syndrome (not due to chronic pathology), |
| obesity (not necessarily considered as disease), sleep apnoea or other     |
| sleep related disorders (usually consequence of disease rather than a     |
| disease itself) which may present with breathlessness                     |
| • Adults with breathlessness as a side effect or adverse reaction to a    |
| drug or medication, or as a result of a medical procedure                 |
| • Unexplained breathlessness                                              |
Table 2: Different Types of Breathlessness Identification and Assessment across Health Care Settings Summary

| Number of studies | Primary care N = 9 | Secondary care N = 53 | SPC N = 35 | Total N = 97 (100%) |
|-------------------|-------------------|----------------------|-----------|-------------------|
| **Identification** | N (%)             | N (%)                | N (%)     | N (%)             |
| Studies using measure to identify presence/absence of breathlessness | 9 (100) | 51 (96.2) | 33 (94.3) | 93 (95.9) |
| **Assessment of symptom severity** |                     |                      | N=70      |                   |
| Studies using measures of breathlessness symptom | 6 (66.7) | 38 (71.7) | 26 (74.3) | 70 (72.2) |
| **Assessment of impact of symptom** |                     |                      | N=55      |                   |
| Studies using impact measures of breathlessness | 6 (66.7) | 33 (62.3) | 16 (45.7) | 55 (56.7) |
| **Measures of the cause/diagnosis of breathlessness** |                     |                      | N=47      |                   |
| Studies using cause/diagnosis measures of breathlessness | 8 (88.9) | 36 (68) | 3 (8.6) | 47 (48.5) |
Records identified through database searching (n = 19,062) (6561 duplicates)

Additional records identified through other sources (n = 3)

Records identified through database searching (n = 19,062)

Additional records identified through other sources (n = 3)

Records after duplicates removed (n = 12,504)

Records screened (n = 12,504)

Records excluded (n = 12,356)

Full-text articles assessed for eligibility (n = 148)

Studies included in narrative synthesis (n = 97)

Full-text articles excluded, with reasons
(n = 51)
Age range < 18 years (n=9)
No age-related information (n=1)
Breathlessness as a result of a procedure/treatment (n=3)
Case histories/studies (n=3)
Conditions not extractable (n=1)
Conditions unclear (n=1)
Conference abstract (n=1)
Duplicate (n=1)
Experimental (n=3)
No conditions matching inclusion criteria (n=11)
No identification/assessment of breathlessness (n=3)
Not routine clinical practice (n=12)
Not in English (n=1)
Not primary research (n=1)

Figure 1: PRISMA Flowchart
Figure 2: Number of studies by health care setting

PC – Primary care
SC - Secondary Care
SPC – Specialist palliative care